Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
- 1 October 2012
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 323 (1), 77-87
- https://doi.org/10.1016/j.canlet.2012.03.034
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Biological reprogramming in acquired resistance to endocrine therapy of breast cancerOncogene, 2010
- Enhancing the Efficacy of Hormonal Agents with Selected Targeted AgentsClinical Breast Cancer, 2009
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionCancer Research, 2008
- Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast CancerClinical Cancer Research, 2005
- Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistanceThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapyEndocrine-Related Cancer, 2004
- Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen DeprivationJournal of Biological Chemistry, 2003
- Aromatase Inhibitors in Breast CancerNew England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002